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Epilepsy is a chronic neurological disease, 
characterized by recurrent seizures resulting from 
abnormal neuronal discharge in the central nervous 
system. Around 65 million subjects are affected by it 
globally.1 Changes in seizure patterns have been 
reported in women during puberty, the menstrual 
cycle, pregnancy and menopause, related to hormone 
steroid levels.2 Estrogens are generally considered 
proconvulsants via the glutamate receptor excitatory 
pathway, while progesterone and its metabolites are 
anticonvulsants via the inhibitory effect via the 
neuronal membrane receptor, enhancing GABA-A 
mediated chloride conductance.2-4 The seizure 
fluctuations that occur during the menstrual cycle are 
responsible for one third of cases and are defined as 
catamenial epilepsy. 2-4 The drug-drug interaction 
between anticonvulsant drugs and contraceptives was 
first suggested in the early 1970s.5 Therefore, 
contraception management in these women is critical 
because of the potential maternal fetal risk due to 
failure in the choice of method.1,6,7 There may also be 
difficulty managing seizure activity, caused by poor 
adherence to the drug treatment or physiological 
changes in the pharmacokinetics of the 
anticonvulsant medication during pregnancy.8 There 
are currently different methods of birth control 
available: non-hormonal contraception such as: 
copper intrauterine devices, barrier methods, surgical  
 
and hormonal, transdermal patches subdermal 
implants, vaginal rings, and finally levonorgestrel-
releasing intrauterine devices. Another form of 
contraceptive use is emergency hormonal 
contraception. The failure rate is approximately 1% in 
healthy women, but 3–6% in women with epilepsy. 
This occurs despite the fact that fertility in this group 
of patients is reduced by one third, either due to social 
reasons or organic reasons.9 The estrogen component 
found in most formulations of oral combined 
contraceptives is ethinylestradiol.  
 
More than 30% of the ethinylestradiol undergoes 
metabolization in the intestinal wall, mainly by 
sulfotransferase - dependent conjugation. 
Subsequently its biotransformation continues in the 
liver catalyzed by cytochrome P450 enzyme complex 
enzymes, uridine diphosphate glucuronyltransferase 
1A1 and sulfotransferase-dependent conjugation, and 
finally, it is hydroxylated to inactive metabolites 
predominantly by cytochrome P450 3A4. These 
hydroxylated and methylated metabolites are present 
free and conjugated to glucuronides and sulfate.9 
Glucuronidation is inhibited by valproate and induced 
by phenobarbital, phenytoin, carbamazepine, 
oxcarbazepine and high dose topiramate, accelerating 
the metabolism of ethinylestradiol.10 Ethinylestradiol 
can  also  induce   the    enzymes   uridine  diphosphate  
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glucuronyl transferase, affecting drugs that are 
primarily metabolized by this pathway, such as 
lamotrigine.9 Similar to ethinylestradiol, the 
metabolism of the progestogen component also 
involves cytochrome P450 by hydroxylation, 
reduction, deacetylation and finally sulfation and 
glucuronidation.9 Its metabolism may be accelerated 
if combined with carbamazepine, oxcarbazepine, 
lamotrigine, phenytoin and phenobarbital.10 The first-
generation of anticonvulsant drugs includes 
phenobarbital, phenytoin, valproate, diazepam, 
clonazepam, carbamazepine, ethosuximide and 
primidone.11 The second-generation drugs include 
felbamate, gabapentin, clobazam, lamotrigine, 
levetiracetam, pregabalin, tiagabine, topiramate, 
vigabatrin and zonisamide.12 
 
Finally, with the aim of obtaining minimal or no 
adverse effects with anticonvulsant properties, the 
door was opened to the third generation: 
brivaracetam, eslicarbazepine acetate, lacosamide, 
rufinamide, stiripentol, perampanel.13 Based on their 
mechanism of hepatic metabolism, anticonvulsant 
drugs may be classified as P450 enzyme-inducing and 
non-enzyme-inducing antiepileptic drugs. P450 
system enzyme inducers include phenobarbital, 
phenytoin, carbamazepine, oxcarbazepine, 
eslicarbazepine, felbamate, primidone, rufinamide, 
lacosamide, and topiramate (at dose greater than 200 
mg/day). These drugs induce the cytochrome P450 
enzymes from the liver, being able to accelerate the 
metabolism of combined or progestogen-only oral 
contraceptives and progestogen implants (subdermal) 
reducing their effectiveness.2,9 
 
Oxcarbazepine has a low enzyme induction potential, 
but unfortunately exerts a similar effect to 
carbamazepine on hormonal contraceptives.9,14 
Therefore, if oral contraception is indicated, use in 
combination with a barrier method such as condom or 
vaginal diaphragm is suggested.15,16 These 
anticonvulsant drugs do not alter the efficacy of depot 
medroxyprogesterone acetate injection, copper 
intrauterine device or levonorgestrel release, therefore 
these may be another option.16 In turn, these drugs 
used as monotherapy increase sex hormone-binding 
globulin levels, both in males and females, resulting in 
decreased levels of testosterone and bioavailable 
estradiol, increasing its metabolism with subsequent 
reduction in its plasma concentration.15 With some 
drugs, the extent of enzyme induction may be dose-
dependent, difficult to quantify and subject to large 
variation between individuals, as occurs with 
topiramate. No enzyme inducers of the P450 system 
are namely levetiracetam, gabapentin, topiramate (at 
doses below 200 mg per day), zonisamide, clobazam, 
tiagabine, brivaracetam and vigabatrin. This group 
does not affect contraceptive efficacy, so epileptic 
women can choose any method of contraception or 
emergency contraception.16 The drug lamotrigine has 
minimal effects on the efficacy of combined 
contraceptives, however, the use of this type of 
contraception increases clearance, reducing the 
plasma concentration of lamotrigine by 45 to 60% and 
predisposing to epilepsy seizures. If this is the option 
chosen by the epileptic woman, the dose of 
lamotrigine should be increased and to reduce its 
toxicity. Along with levetiracetam, it is recommended 
during pregnancy because of its low risk of 
teratogenicity. Enzyme inhibitor anticonvulsant drugs 
valproate is used as a first option in many women with 
generalized epilepsy and in unclassified epilepsy, 
achieving control with low doses. It is highly 
teratogenic in a dose-dependent manner, and genetic 
factors and individual susceptibility may be involved. 
It has been described to act as an antagonist of folic 
acid.17 A significantly lower intelligence quotient was 
detected in children of women treated with valproate, 
as well as a lower verbal, nonverbal and spatial 
response and the need for an 8-fold higher education 
intervention. Intrauterine exposure to this drug is 
associated with an increased risk of autism spectrum 
disorders, hyperactivity, dyspraxia and attention 
deficit disorder.8 Stiripentol inhibits cytochrome P450 
3A4. There are no publications on the interaction of 
this drug with contraceptives, so its action on this 
pathway is assumed to be mild.14 
 
Literature suggests increase in risk of seizures during 
contraception. A birth control registry was conducted 
in 1144 epileptic women, aged 18 to 47 years to find out 
the impact of contraceptive methods on seizures in 
different antiepileptic drug category users. For each 
category of anticonvulsant drugs, they reported an 
approximately 4.5-fold increased risk of seizures while 
taking hormonal contraception versus non-
hormonal.3 Within specific types of hormonal 
contraception, a 68% higher incidence of seizures was 
reported with hormonal patches when compared to 
users of combined oral contraceptives, probably due 
to higher ethinylestradiol levels, because 
gastrointestinal absorption and the first step of 
hepatic metabolism are avoided.3 And those who used 
the progestogen-only contraceptive pill had a 62% 
increase in seizures. This could be due to the low 
progestin content; whose contraceptive action is more 
RV15 
 
 International Healthcare Research Journal 2021;5(1):RV14-RV18.  
Anti-Epileptic Drugs and Contraceptives                                                                                                                                     Sharma B et al.  
on cervical mucus than on hormone suppression. 
Within monotherapy, lamotrigine and valproate 
presented increased attacks when combined with 
hormonal contraception.1,3 The precise mechanism by 
which hormonal based contraceptives may increase 
the risk of epileptic seizures remains unknown, as 
there is little evidence regarding the neuroactive 
properties of the synthetic steroids of contraceptives.  
 
Three potential pathways have been proposed: by 
classic genomic action estrogens in the central 
nervous system binds to specific receptors, dimerize 
and modify neuronal gene expression. Due to 
nongenomic effects through membrane receptor 
activation, regardless of the pathway, they can 
generate changes in neuronal structure, plasticity, 
direct excitatory effects on the neuronal membrane 
and postsynaptic regulation of different 
neurotransmitters. Finally, indirect effects due to 
alteration of the metabolism of anticonvulsant drugs 
via induction of the hepatic cytochrome P450 enzyme 
system, leading to drug-drug interactions and thus 
reducing therapeutic efficacy when administered 
together.1,4 A retrospective, observational cohort study 
with case-control analysis was described, conducted 
from the United Kingdom Health Improvement 
Network database with 2,201 epileptic women aged 20 
to 44 years. This study showed no association between 
combined oral contraceptives or the progestogen-only 
hormonal pill and the risk. of epilepsy. However, the 
limitation of this study was low utilization of 
contraceptives.18 Another study on epileptic women 
reported that 63% had received family planning 
information, however, 54% reported a previous 
pregnancy. About half of these women were not using 
contraception and among those who were users, 11% 
were at risk of potential interaction between oral 
contraceptives and enzyme-inducing anti-epileptic 
drugs. 80% received folic acid during pregnancy, 
although most started supplementation in the second 
trimester of pregnancy.19  
 
Another study reports that 65% of the women had had 
at least one unwanted pregnancy, 30.3% of them did 
not use a contraceptive method considered highly 
effective, correlated to lower income, younger age and 
less access to health insurance.20 14.5% used hormonal 
contraception in combination with enzyme-inducing 
anti-epileptic drugs that could compromise 
contraceptive efficacy and 50% did not take folic acid 
before or during pregnancy. Among users with 
reversible contraceptive methods, 40.6% discontinued 
it. When compared with the various anti-epileptic 
drugs, combination with enzyme inducers most 
commonly caused the discontinuation of 
contraceptive methods. Only 25.4% of epileptic 
women had consulted with their neurologist 
regarding the choice of contraceptive method. The 
most common reasons for discontinuation were 
concern about reliability (13.9%), menstrual problems 
(13.5%) and increased seizures (8.6%).21 A study by 
Espinera et al. showed how counselling with the 
epileptologist may influence the choice of 
contraceptive method.22 Patients who did not desire to 
get pregnant, when advised about the intrauterine 
device as a first choice of birth control, were more 
willing to change to this contraceptive method and 
were more successful if this topic was addressed at the 
first neurological consultation. Another survey of 
neurologists from Brazil reported that 76% conducted 
family planning counseling, 81% recommended the 
use of copper intrauterine device, 60% simultaneously 
prescribed anticonvulsant drugs and hormonal 
contraception. Although 93% were aware that it could 
contraindicate the use of some contraceptives, they 
were unaware of the specific mechanism of interaction 
between both drugs.23 
 
During pregnancy, most epileptic women experience 
improvement of epilepsy, especially those treated with 
monotherapy and even remain seizure-free, as 
demonstrated by the European and International 
Registry of Antiepileptic Drugs and Pregnancy.24 Only 
2.6% of pregnant women needed to increase the dose 
or add a second anticonvulsant drug. In addition, 
there is a 4.9% risk of malformations in children of 
women receiving anticonvulsants during pregnancy 
versus 2.2% in the general healthy population. The use 
of an anticonvulsant drug in monotherapy doubles the 
risk, while combination therapy triples it. Prior folic 
acid supplementation is associated with 
neurodevelopmental benefits, where children born to 
pharmacologically treated epileptic mothers, without 
prior exposure to folic acid, are at increased risk of 
autistic traits, and this is inversely associated with 
maternal plasma folate concentration and folic acid 
dose. Therefore, when planning to get pregnant, it is 
recommended to start taking folic acid, at least until 
the first trimester of pregnancy. 
 
CONCLUSION 
Epilepsy in women is influenced by physiological 
variations in the secretion of sex hormones during the 
menstrual cycle in reproductive life. Therefore, it is 
important to know aspects of treatment that are 
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specific at this stage, such as the combination of 
anticonvulsant drugs and contraceptives, menstrual 
cycle-related seizures and their adverse effects. It is 
important to discuss with epileptic patients regarding 
the adverse effects, preference, efficacy, risks and 
benefits of the different methods of contraception, as 
well as the possible interactions with some 
anticonvulsant drugs in order to optimize the best 
method. With advancement in the pharmaceutical 
industry, we have a greater selection of anticonvulsant 
drugs, with better efficacy and tolerance and fewer 
drug interactions. The concept of monotherapy or 
rational combination therapy is important in women 
who are sexually active and who do not want to 
conceive, so they should be oriented on the most 
effective form of contraception. 
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